Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms

Cancer Science

Volumn 108, Issue 10, 2017, Pages 1907-1912

  Araki, Marito ^a   Komatsu, Norio ^a  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Autocrine; calreticulin; JAK2; myeloproliferative neoplasm; thrombopoietin receptor

Indexed keywords

CALRETICULIN; THROMBOPOIETIN RECEPTOR; CALRETICULIN, HUMAN; MPL PROTEIN, HUMAN; PROTEIN BINDING;

AMINO TERMINAL SEQUENCE; AUTOCRINE EFFECT; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL SURFACE; CELL TRANSFORMATION; CONFORMATIONAL TRANSITION; EXON; FRAMESHIFT MUTATION; GENE EXPRESSION; HUMAN; MOLECULAR PATHOLOGY; MUTANT; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; READING FRAME; REVIEW; WILD TYPE; BINDING SITE; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MYELOPROLIFERATIVE DISORDER; SIGNAL TRANSDUCTION;

AUTOCRINE COMMUNICATION; BINDING SITES; CALRETICULIN; CELL TRANSFORMATION, NEOPLASTIC; FRAMESHIFT MUTATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MYELOPROLIFERATIVE DISORDERS; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, THROMBOPOIETIN; SIGNAL TRANSDUCTION;

EID: 85030155677     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.13327     Document Type: Review

References (54)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–74.
2. Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–90.
3. Levine RL, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–97.
4. James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–8.
5. Baxter EJ, Scott LM, Campbell PJ et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–61.
6. Pikman Y, Lee BH, Mercher T et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.
7. Tiedt R, Hao-Shen H, Sobas MA et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008; 111: 3931–40.
8. Shide K, Shimoda HK, Kumano T et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia 2008; 22: 87–95.
9. Xing S, Wanting TH, Zhao W et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 2008; 111: 5109–17.
10. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010; 115: 3589–97.
11. Marty C, Lacout C, Martin A et al. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood 2010; 116: 783–7.
12. Li J, Spensberger D, Ahn JS et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 2010; 116: 1528–38.
13. Hasan S, Lacout C, Marty C et al. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNalpha. Blood 2013; 122: 1464–77.
14. Klampfl T, Gisslinger H, Harutyunyan AS et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379–90.
15. Nangalia J, Massie CE, Baxter EJ et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391–405.
16. Ostwald TJ, MacLennan DH. Isolation of a high affinity calcium-binding protein from sarcoplasmic reticulum. J Biol Chem 1974; 249: 974–9.
17. Fliegel L, Burns K, MacLennan DH, Reithmeier RA, Michalak M. Molecular cloning of the high affinity calcium-binding protein (calreticulin) of skeletal muscle sarcoplasmic reticulum. J Biol Chem 1989; 264: 21522–8.
18. Smith MJ, Koch GL. Multiple zones in the sequence of calreticulin (CRP55, calregulin, HACBP), a major calcium binding ER/SR protein. EMBO J 1989; 8: 3581–6.
19. Wada I, Rindress D, Cameron PH et al. SSR alpha and associated calnexin are major calcium binding proteins of the endoplasmic reticulum membrane. J Biol Chem 1991; 266: 19599–610.
20. David V, Hochstenbach F, Rajagopalan S, Brenner MB. Interaction with newly synthesized and retained proteins in the endoplasmic reticulum suggests a chaperone function for human integral membrane protein IP90 (calnexin). J Biol Chem 1993; 268: 9585–92.
21. Nakamura K, Zuppini A, Arnaudeau S et al. Functional specialization of calreticulin domains. J Cell Biol 2001; 154: 961–72.
22. Goicoechea S, Orr AW, Pallero MA, Eggleton P, Murphy-Ullrich JE. Thrombospondin mediates focal adhesion disassembly through interactions with cell surface calreticulin. J Biol Chem 2000; 275: 36358–68.
23. Gao B, Adhikari R, Howarth M et al. Assembly and antigen-presenting function of MHC class I molecules in cells lacking the ER chaperone calreticulin. Immunity 2002; 16: 99–109.
24. Ogden CA, de Cathelineau A, Hoffmann PR et al. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med 2001; 194: 781–95.
25. Gardai SJ, McPhillips KA, Frasch SC et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005; 123: 321–34.
26. Sipione S, Ewen C, Shostak I, Michalak M, Bleackley RC. Impaired cytolytic activity in calreticulin-deficient CTLs. J Immunol 2005; 174: 3212–9.
27. Denning GM, Leidal KG, Holst VA et al. Calreticulin biosynthesis and processing in human myeloid cells: demonstration of signal peptide cleavage and N-glycosylation. Blood 1997; 90: 372–81.
28. Kapoor M, Srinivas H, Kandiah E et al. Interactions of substrate with calreticulin, an endoplasmic reticulum chaperone. J Biol Chem 2003; 278: 6194–200.
29. Kapoor M, Ellgaard L, Gopalakrishnapai J et al. Mutational analysis provides molecular insight into the carbohydrate-binding region of calreticulin: pivotal roles of tyrosine-109 and aspartate-135 in carbohydrate recognition. Biochemistry 2004; 43: 97–106.
30. Baksh S, Spamer C, Heilmann C, Michalak M. Identification of the Zn2 + binding region in calreticulin. FEBS Lett 1995; 376: 53–7.
31. Guo L, Groenendyk J, Papp S et al. Identification of an N-domain histidine essential for chaperone function in calreticulin. J Biol Chem 2003; 278: 50645–53.
32. Frickel EM, Riek R, Jelesarov I, Helenius A, Wuthrich K, Ellgaard L. TROSY-NMR reveals interaction between ERp57 and the tip of the calreticulin P-domain. Proc Natl Acad Sci USA 2002; 99: 1954–9.
33. Martin V, Groenendyk J, Steiner SS et al. Identification by mutational analysis of amino acid residues essential in the chaperone function of calreticulin. J Biol Chem 2006; 281: 2338–46.
34. Baksh S, Michalak M. Expression of calreticulin in Escherichia coli and identification of its Ca2 + binding domains. J Biol Chem 1991; 266: 21458–65.
35. Schrag JD, Bergeron JJ, Li Y et al. The Structure of calnexin, an ER chaperone involved in quality control of protein folding. Mol Cell 2001; 8: 633–44.
36. Ellgaard L, Riek R, Herrmann T et al. NMR structure of the calreticulin P-domain. Proc Natl Acad Sci USA 2001; 98: 3133–8.
37. Kozlov G, Pocanschi CL, Rosenauer A et al. Structural basis of carbohydrate recognition by calreticulin. J Biol Chem 2010; 285: 38612–20.
38. Chouquet A, Paidassi H, Ling WL et al. X-ray structure of the human calreticulin globular domain reveals a peptide-binding area and suggests a multi-molecular mechanism. PLoS ONE 2011; 6: e17886.
39. Mondet J, Park JH, Menard A et al. Endogenous megakaryocytic colonies underline association between megakaryocytes and calreticulin mutations in essential thrombocythemia. Haematologica 2015; 100: e176–8.
40. Araki M, Yang Y, Masubuchi N et al. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood 2016; 127: 1307–16.
41. Marty C, Pecquet C, Nivarthi H et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood 2016; 127: 1317–24.
42. Elf S, Abdelfattah NS, Chen E et al. Mutant calreticulin requires both its mutant c-terminus and the thrombopoietin receptor for oncogenic transformation. Cancer Discov 2016; 6: 368–81.
43. Chachoua I, Pecquet C, El-Khoury M et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood 2016; 127: 1325–35.
44. Shide K, Kameda T, Yamaji T et al. Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib. Leukemia 2017; 31: 1136–44.
45. Tefferi A, Wassie EA, Guglielmelli P et al. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 2014; 89: E121–4.
46. Pietra D, Rumi E, Ferretti VV et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 2016; 30: 431–8.
47. Brooks AJ, Dai W, O'Mara ML et al. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science 2014; 344: 1249783.
48. Matthews EE, Thevenin D, Rogers JM et al. Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulation. FASEB J 2011; 25: 2234–44.
49. Staerk J, Defour JP, Pecquet C et al. Orientation-specific signalling by thrombopoietin receptor dimers. EMBO J 2011; 30: 4398–413.
50. Dupuis M, Schaerer E, Krause KH, Tschopp J. The calcium-binding protein calreticulin is a major constituent of lytic granules in cytolytic T lymphocytes. J Exp Med 1993; 177: 1–7.
51. Eggleton P, Lieu TS, Zappi EG et al. Calreticulin is released from activated neutrophils and binds to C1q and mannan-binding protein. Clin Immunol Immunopathol 1994; 72: 405–9.
52. Han L, Schubert C, Kohler J et al. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion. J Hematol Oncol 2016; 9: 45.
53. Obata Y, Toyoshima S, Wakamatsu E et al. Oncogenic Kit signals on endolysosomes and endoplasmic reticulum are essential for neoplastic mast cell proliferation. Nat Commun 2014; 5: 5715.
54. Choudhary C, Olsen JV, Brandts C et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 2009; 36: 326–39.